P
Phio Pharmaceuticals Corp.
PHIOCIK 0001533040NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31
Period
FY 2025
Revenue
—
Net Income
$-8.70M
Total Assets
$21.49M
Equity
$20.15M
Shares Out
11.62M
Op. Cash Flow
$-7.98M
Business
Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company developing therapeutics using its proprietary INTASYL small interfering RNA gene silencing technology to make immune cells more effective at killing tumor cells. It develops INTASYL compounds, including PH-762 (designed to reduce PD-1 expression) and PH-894 (designed to silence BRD4), for direct-to-tumor and adoptive cell therapy applications. The company operates as a single Clinical operating and reporting segment focused on clinical development, intellectual property and collaborative programs. Phio conducts U.S. clinical trials, relies on third-party contract manufacturers and CROs, and pursues regulatory approvals in the U.S. and other jurisdictions including EU, UK, Canada and Japan.
Summary from filing dated 2025-03-31
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development | 5 | 4 | 6 | 7 | 9 | |
| General and administrative | 5 | 4 | 4 | 4 | 5 | |
| Total operating expenses | 9 | 7 | 11 | 11 | 14 | |
| Operating loss | −9 | −7 | −11 | −11 | −14 | |
| Interest income, net | 520,000 | 231,000 | — | — | — | |
| Other income, net | 2,000 | 6,000 | — | — | — | |
| Net loss | −9 | −7 | −11 | −11 | −13 | |
| Basic and diluted (in dollars per share) | −1.45 | −9.08 | −46.76 | −10.1 | −12.43 | |
| Basic and diluted (in shares) | 6 | 787,466 | 231,508 | 1 | 1 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 21 | 5 | 8 | — | — | |
| Prepaid expenses and other current assets | 445,000 | 354,000 | 832,000 | 615,000 | 620,000 | |
| Total current assets | 21 | 6 | 9 | 12 | 25 | |
| Property and equipment, net | 11,000 | 2,000 | 6,000 | 183,000 | 133,000 | |
| Total assets | 21 | 6 | 9 | 13 | 25 | |
| Accounts payable | 435,000 | 253,000 | 657,000 | 779,000 | 283,000 | |
| Accrued expenses | 905,000 | 762,000 | 942,000 | 1 | 3 | |
| Total liabilities | 1 | 1 | 2 | 2 | 3 | |
| Commitments and contingencies | — | — | — | — | — | |
| Series D Preferred stock, $0.0001 par value, 10,000,000 shares authorized; 0 issued and outstanding at each of December 31, 2025 and December 31, 2024 | 0 | 0 | — | — | 0 | |
| Common stock, $0.0001 par value, 100,000,000 shares authorized; 11,617,250 and 1,733,717 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 1,000 | 0 | 0 | 0 | 0 | |
| Additional paid-in capital | 175 | 151 | 147 | 139 | 139 | |
| Accumulated deficit | −155 | −146 | −139 | −128 | −117 | |
| Total stockholders' equity | 20 | 5 | 8 | 11 | 22 | |
| Total liabilities and stockholders' equity | 21 | 6 | 9 | 13 | 25 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation and amortization | 3,000 | 2,000 | 56,000 | 71,000 | 75,000 | |
| Amortization of right of use asset | 0 | 33,000 | 128,000 | 122,000 | 117,000 | |
| Net gain/(loss) on disposal of property and equipment | 0 | −6,000 | — | — | — | |
| Stock-based compensation | 481,000 | 147,000 | 303,000 | 414,000 | 480,000 | |
| Prepaid expenses and other assets | −91,000 | 481,000 | −196,000 | 8,000 | 241,000 | |
| Accounts payable | 183,000 | −404,000 | −122,000 | 496,000 | −445,000 | |
| Accrued expenses | 143,000 | −180,000 | −83,000 | −2 | 1 | |
| Lease liability | 0 | −35,000 | −135,000 | −125,000 | −116,000 | |
| Net cash (used in) operating activities | −8 | −7 | −11 | −12 | −12 | |
| Cash paid for purchase of property and equipment | −12,000 | −1,000 | −5,000 | −121,000 | −51,000 | |
| Asset sale proceeds | 0 | 9,000 | — | — | — | |
| Net cash (used in) provided by investing activities | −12,000 | 8,000 | −5,000 | −121,000 | −51,000 | |
| Net proceeds from the exercise of warrants | 6 | 4 | — | 0 | 2 | |
| Net proceeds from the issuance of common stock and warrants | 18 | 0 | — | — | — | |
| Cash-in-lieu of fractional shares from reverse stock split | 0 | −1,000 | — | — | — | |
| Payments to repurchase shares withheld for payroll taxes from restricted stock issuance | −30,000 | −5,000 | −26,000 | −28,000 | −1,000 | |
| Net cash provided by financing activities | 24 | 4 | 7 | −26,000 | 22 | |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 16 | −3 | — | — | — | |
| Interest paid | 0 | 13,000 | 11,000 | — | 8,000 |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro